Christopher Lock, MD, spoke with Healio about findings from the Evoke and Evoke+ trials presented at the 2026 American Academy of Neurology Annual Meeting.
May 19, 2026
1 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
In this Healio video, Christopher Lock, MD, discusses highlights in anti-amyloid therapies for Alzheimer’s disease presented at…
In this Healio video, Christopher Lock, MD, discusses advances in Alzheimer’s disease treatment and diagnosis presented at the…
Compared with placebo, semaglutide was associated with improved quality of life outcomes for patients with type 2 diabetes and…
Christopher Lock, MD, spoke with Healio about takeaways on the impact of lifestyle factors on Alzheimer’s disease presented at…
Once-weekly injectable semaglutide 2.4 mg was linked to reductions in body weight and improvements in multiple cardiometabolic…
We are living in an exciting new era for Alzheimer’s treatment. For the first time, therapies can slow the disease for some…
